Investigating the role of immunoglobulin replacement therapy in patients receiving CAR-T cell therapy for B cell malignancies
Official title: Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy
Funded at Fred Hutchinson Cancer Center · NIH-10915043 · Data updated 2026-11-12
This study is looking at how immunoglobulin replacement therapy might help patients who have received CAR-T cell therapy for B cell cancers by seeing if it can lower their chances of getting infections compared to a placebo, while also checking how it affects their CAR-T cells and healthcare needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $858,502 |
| NIH project number | 5R01CA276040-02 |
| Project ID | NIH-10915043 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older who have received CD19-targeted CAR-T cell therapy for B cell malignancies and are experiencing hypogammaglobulinemia.
✕Less likely to help
Patients who have not undergone CAR-T cell therapy or those without hypogammaglobulinemia may not benefit from this research.
What this research studies
This research focuses on understanding how immunoglobulin replacement therapy (IGRT) affects patients who have undergone CD19-targeted CAR-T cell therapy for B cell malignancies. The study aims to determine whether IGRT can reduce infection rates in these patients compared to a placebo, while also examining its impact on CAR-T cell function and overall healthcare resource utilization. By conducting a randomized, controlled trial, the research seeks to provide critical insights into the benefits and risks associated with IGRT in this specific patient population.
Why it matters
Potential benefit: If successful, this research could lead to improved infection prevention strategies for patients undergoing CAR-T cell therapy, enhancing their overall treatment outcomes.
How similar studies have gone: This research is novel as it represents the first randomized, controlled trial specifically examining the use of immunoglobulin replacement therapy in CAR-T cell therapy recipients.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Hill, Joshua Aiden — Fred Hutchinson Cancer Center
- Study coordinator: Hill, Joshua Aiden
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.